SCHEMBL5366877

SCHEMBL5366877

Cc1c(Br)ccc2c1C(=Cc1nn(C)cc1Cl)C(=O)N2

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.34
HPGD P15428 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
GSK3B P49841 2/20 0.33
TGM2 P21980 2/20 0.33
ALDH1A1 P00352 2/20 0.33
KDM4E B2RXH2 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
LRRK2 Q5S007 2/20 0.32
MDM2 Q00987 1/20 0.32
PSEN1 P49768 1/20 0.32
PSEN2 P49810 1/20 0.32
APH1B Q8WW43 1/20 0.32
NCSTN Q92542 1/20 0.32
APH1A Q96BI3 1/20 0.32
PSENEN Q9NZ42 1/20 0.32
RAF1 P04049 1/20 0.32
PDPK1 O15530 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7135989 0.82 SIRT1 (0.32) MAPTALDH1A1
SCHEMBL5999807 0.75 GSK3B (0.58) MAPTMEN1KMT2AGSK3BTDP1
SCHEMBL5999800 0.75 GSK3B (0.58) MAPTMEN1KMT2AGSK3BTDP1
SCHEMBL7131400 0.75 MEN1 (0.42) MEN1KMT2AGSK3BTGM2MDM2
SCHEMBL5368564 0.75 MEN1 (0.50) MAPTHPGDMEN1KMT2AALDH1A1
SCHEMBL7134022 0.74 LRRK2 (0.48) LRRK2MDM2PSEN1PSEN2APH1B
SCHEMBL5359703 0.74 RET (0.37) MEN1KMT2AGSK3BMDM2PDPK1
SCHEMBL7133405 0.74 LRRK2 (0.46) LRRK2PSEN1PSEN2APH1BNCSTN
SCHEMBL5370004 0.74 MAPT (0.50) MAPTHPGDMEN1KMT2AGSK3B
SCHEMBL7140872 0.73 MDM2 (0.51) TGM2LRRK2MDM2PSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK MAPT 3048/4885HPGD 1435/4885MEN1 3855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.